CLARITY AND FOCUS FOR PATIENTS WITH SCHIZOPHRENIA

Introducing the first prescription digital therapy designed to treat schizophrenia

THRIVETM: FOR SCHIZOPHRENIA

Pear Therapeutics has developed THRIVETM, a mobile medical application to be used in conjunction with medication for treating schizophrenia

Medication Plus Patient-Facing Smartphone Application

Clinician-Facing Web Interface

WHAT IS THRIVETM?

  • THRIVETM is a clinically validated digital intervention applying evidence-based, multi-modal and reinforcement therapy.  It is comprised of a patient-facing smartphone application and clinician-facing web interface.
  • THRIVETM is a digital therapy that provides 24/7, real-time patient monitoring and support.
  • THRIVETM provides real-time interventions targeting positive symptoms of schizophrenia including hallucinations and delusions, and also provides support for schizophrenia-related mood disorders.

THRIVETM AS A TREATMENT TOOL FOR SCHIZOPHRENIA

THRIVETM enhances the efficacy of atypical anti-psychotics for schizophrenia

A 30-day trial of THRIVETM shows significant reduction in the following:

thrive_graph1
thrive_graph2
thrive_graph3
thrive_graph4

 

  • 33 patients on anti-psychotic medications were given access to THRIVETM and their symptoms were evaluated for 30 days.
  • After 30 days of therapy, patients showed an average 8% reduction in Positive and Negative Syndrome Scale (PANSS).
  • Patients were highly satisfied with THRIVETM, interacting with the application an average of 5.2 times per day.  63% of the use was initiated by patients.
Ben-Zeev et al. Schizophrenia Bull. 2014.

LARGEST AND LONGEST IMPLEMENTATION STUDY RESULTS RELEASED

342 patient real-world usability study examining THRIVETM for 6 months of treatment after discharge from the hospital

  • The study demonstrated robust usage and engagement suggesting that THRIVETM could be an efficacious, long-lived therapeutic intervention.
  • 74% of patients used the THRIVETM program successfully during this high-risk period for 3-6 months.
  • On average, participants used THRIVETM for 82% of weeks they had digital therapeutic.
Ben-Zeev et al. JMIR Mental Health. 2016.

PEAR'S ACADEMIC PARTNERS ARE CURRENTLY CONDUCTING ADDITIONAL TRIALS EXAMINING EFFICACY IN SCHIZOPHRENIA

  • In 2016, Pear’s academic partners will conduct a randomized controlled trial (RCT, n=40 people with schizophrenia) of THRIVETM vs Treatment as Usual
  • In 2016, Pear’s academic partners will start a 2.5 year RCT comparing THRIVETM to a clinic-based group intervention (n=160 people with severe mental illness)

For more information, please contact us

Contact Us

*THRIVETM is not yet available for sale in the United States